Cancer News

Revlimid® Reduces Need for Blood Transfusions in Some Myelodysplastic Syndromes (08/31/2016)

The agent Revlimid (lenalidomide) reduces the need for blood transfusions among patients with lower-risk, non-del (5q) myelodysplastic syndromes who are dependent upon red blood cell transfusions, but are not eligible for erythropoiesis-stimulating agents. These results were recently published in the Journal of Clinical Oncology. Myelodysplastic syndromes (MDS) refer to a group of diseases in which … Continue reading "Revlimid® Reduces Need for Blood Transfusions in Some Myelodysplastic Syndromes"